Scientists track Long-Term safety of experimental AMD therapy
NCT ID NCT07660640
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows people with advanced dry age-related macular degeneration who previously received a one-time injection of the experimental treatment VOY-101. Researchers are monitoring participants over the long term to check for any side effects related to the treatment. The goal is to understand the safety profile of VOY-101 beyond the initial study period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VOY-101
What this could lead to
If successful, this long-term safety data could support further development of VOY-101 as a potential treatment for advanced dry age-related macular degeneration.
What could go wrong
This is an observational follow-up study, not a new treatment trial. It cannot prove whether VOY-101 works; it only tracks safety over time. The number of participants is small.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ophthalmic Consultants of Boston
Boston, Massachusetts, 02114, United States
-
Retina Consultants of Texas
Bellaire, Texas, 77401, United States
-
Sourasky Medical Center - Ichilov
Tel Aviv, 6423906, Israel
-
University of Utah
Salt Lake City, Utah, 84132, United States